Sutro Biopharma

Sutro Biopharma: Focused on developing next generation antibody drug conjugates (ADCs) and other complex biologics for cancer through its proprietary cell-free platform, a scalable biochemical cell-free protein synthesis platforms that enable rapid and systematic evaluation of protein structure-activity relationships. The company’s FolRα-targeting ADC (STRO-002) in ovarian cancer is currently in Ph 1 with dose-expansion data expected in 2H 2021. Enrollment is ongoing for CD74-targeting ADC (STRO-001) in the Ph 1 dose-escalation in B-cell malignancies. Additional programs in preclinical/discovery are Tissue Factor ADC, ROR1 ADC, IL-12, IFNα, 5T4-TCE bispecific. Sutro has three high value collaborations with BMS (BCMA ADC), Merck (cytokines), and EMD Serono (MUC1-EGFR bispecific ADC).
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Infectious Disease, Oncology
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Antibodies, Platform Technology
310 Utah Ave
Suite 150
South San Francisco, CA 94080
United States

Company Participants at Solebury Trout Virtual Management Access Event 2021

Bill Newell
Sutro Biopharma, Chief Executive Officer
William J. Newell has served as our Chief Executive Officer and a member of our Board of Directors since January 2009. Previously, he served as the President of Aerovance, Inc., a biotechnology company focused on respiratory diseases, from 2006 to 2007. Mr. Newell has also served as the Chief Business Officer and Senior Vice President at QLT Inc., in several senior management positions at Axys Pharmaceuticals, Inc., and has experience as a corporate lawyer. He currently serves on the boards of directors of Biotechnology Innovation Organization’s Health Section and Emerging Company Section and the California Life Sciences Association, where he also serves as a member of the executive committee. Mr. Newell received an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan Law School. We believe that Mr. Newell is qualified to serve on our Board of Directors because of his experience with various biotechnology companies, including working with and serving in various executive positions in life sciences companies.

Top 10 Holders of Sutro Biopharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
The Vanguard Group, Inc. 6.56 3,033,150 32.45 Funds 11/30/21
Franklin Advisers, Inc. 6.36 2,934,354 31.40 13F 9/30/21
Suvretta Capital Management LLC 5.21 2,408,395 25.77 Stakes 11/30/21
Eventide Asset Management LLC 5.14 2,370,975 25.37 13F 9/30/21
First Light Asset Management LLC 4.75 2,191,439 23.45 13F 9/30/21
Vanguard Group, Inc. (Subfiler) 4.45 2,052,001 21.96 13F 9/30/21
BlackRock Fund Advisors 4.19 1,934,581 20.70 13F 9/30/21
SV Health Investors LLC 3.95 1,824,542 19.52 13F 9/30/21
Baillie Gifford & Co. 3.89 1,794,940 19.21 13F 9/30/21
State Street Corp. 3.69 1,702,350 18.22 13F 9/30/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.